Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer. Nierengarten MB. Cancer 2023;129:2278.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer. Cancer 2023;129:2278.
PMID: 37401895